



GP  
1804

18X  
Ziska

#7

PATENT  
Atty Dkt 4364-0002.24

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 24 Feb 1995.

24 Feb 1995  
Date

Regina Bruckhaus  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Raju Kucherlapati et al.

Serial No.: 08/234,145

Group Art Unit: 1806

Filing Date: 28 April 1994

Examiner: Unassigned

Title: GENERATION OF XENOGENEIC  
ANTIBODIES

RECEIVED  
MAR 21 1995  
GROUP 1806

SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

In addition to the Information Disclosure Statement Under 37 CFR 1.97 mailed to the PTO on 28 July 1994, the citations on the attached sheet, copies attached, were cited in an International Search Report (copy attached) in the corresponding European Application and may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure as defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in the application.

1. U.S. Patent No. 4,959,313 to Taketo issued on 25 September 1990.
2. U.S. Patent No. 4,950,599 to Bertling issued on 21 August 1990.

3. Yamaura et al., "Cell-Type-Specific and Regulated Expression of a Human  $\gamma$ 1 Heavy-Chain Immunoglobulin Gene in Transgenic Mice", *Proc. Natl. Acad. Sci., USA* 83:2152-2156 (1986).
4. Ayares et al., "Sequence Homology Requirements for Intermolecular Recombination in Mammalian Cells", *Proc. Natl. Acad. Sci. USA* 83:5199-5203 (1986).
5. Brinster et al., "Introns Increase Transcriptional Efficiency in Transgenic Mice", *Proc. Natl. Acad. Sci., USA* 85:836-840 (1988).
6. Kucherlapalati, R., "Homologous Recombination in Mammalian Somatic Cells", *Prog. Nucleic Acid Res. Mol. Biol.* 36:301-310 (1989).
7. Shimizu et al., "Immunoglobulin Double-Isotype Expression by Trans-mRNA in a Human Immunoglobulin Transgenic Mouse", *Proc. Natl. Acad. Sci., USA* 86:8020-8023 (1989).

This Information Disclosure Statement is submitted before receipt of the first Office Action on the merits. Therefore, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper to Deposit Account Number 03-1952.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that this citation constitutes prior art under 35 U.S.C. § 102.

Respectfully submitted,

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

MORRISON & FOERSTER  
2000 Pennsylvania Avenue, N.W.  
Washington, D.C. 20006-1812  
Tel: (202) 887-1500  
Fax: (202) 887-0763